Merck provides upgraded manufacturing capabilities to BioInvent

Science and technology company, Merck, has announced that it will be providing Swedish company, BioInvent, a full line of its Mobius single-use bioreactors for the upgrade and expansion of its drug manufacturing facility.

BioInvent will add four bioreactors (ranging from three-litre to 1000-litre) to its upstream facility in Lund, Sweden. The addition of the manufacturing scale single-use bioreactor (1000 litre) will enable the company to meet production requirements for its own antibody development projects and those of its global customers.

“BioInvent has been discovering and manufacturing antibodies for more than 30 years, and when we decided to upgrade our single-use production facility, we established very demanding requirements,” said Kristoffer Rudenholm Hansson, vice president of technical operations at BioInvent. “Merck’s single-use bioreactors most effectively addressed our current and future needs with a fully scalable system.”